An observational study in Depression - Major Depressive Disorder and Cognition Disorders in Old Age, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Recruiting at 1 site in Poland. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Depression with a site in Poland — 18 open to participants now, 22 under way, 7 of them phase 3. Depression · Poland.
Among the 94 studies in Depression with a site in Poland, this one is the 11th largest by planned enrollment of the 14 observational ones that give a count, is one of 16 that started in 2025, is one of 14 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 88th registered.
8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.
Browse Depression studies →18 of the 94 studies in Depression with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Draig Therapeutics Ltd · Sites in Poland, United States, Bulgaria and 2 more countries
Ages 18–75
Cybin IRL Limited · Sites in Poland, United States, Australia and 5 more countries
Ages 18–85
Seaport Therapeutics · Sites in Poland, United States, Bulgaria and 4 more countries
Ages 18–65
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 15 · Phase 3 32 · Phase 4 1
First in 2004; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 220 across the 80 interventional studies, 391 across the 14 observational. Of the 65 that completed or were terminated, 22 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aziende Chimiche Riunite Angelini Francesco S.p.A, one of the names counted as Angelini Pharma. Under that name alone:
Aziende Chimiche Riunite Angelini Francesco S.p.A is the lead sponsor of 40 studies on the registry; 1 is open to participants now.
Angelini Pharma has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
10 of the studies in Depression with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT07377682Aziende Chimiche Riunite Angelini Francesco S.p.AReal-world Clinical Response to Trazodone in Italy, Poland, and Romania | 2026-12 |
| NCT06363981Jakub AntczakMultisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Depression with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data from standard clinical practice in Italy, Poland, and Romania
Patients with Major Depressive Disorder and mild cognition impairment treated with trazodone
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Depressive symptoms severity (MADRS)
To describe the response in terms of depressive symptoms severity (as measured by Montgomery-Åsberg Depression Rating Scale \[MADRS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a widely used clinician-rated scale designed to measure the overall severity of core symptoms of depression in patients with MDD. It consists of 10 items: nine of the items are based upon patient report and one is on the rater's observation during the rating interview. MADRS items are rated on a 7-point scale, where 0 refers to the lack of the symptom and 6 refers to the most severe level of the symptom. The total score is the sum of the items and ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. The MADRS is completed by the Investigator at each scheduled visit and the results will be entered into the eCRF.
Time frame: At 24 weeks from treatment
Depressive symptoms severity (MADRS)
To describe the response in terms of depressive symptoms severity (as measured by MADRS) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a widely used clinician-rated scale designed to measure the overall severity of core symptoms of depression in patients with MDD. It consists of 10 items: nine of the items are based upon patient report and one is on the rater's observation during the rating interview. MADRS items are rated on a 7-point scale, where 0 refers to the lack of the symptom and 6 refers to the most severe level of the symptom. The total score is the sum of the items and ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. The MADRS will be completed by the Investigator at each scheduled visit and the results will be entered into the eCRF.
Time frame: At 12 weeks from treatment
Clinical response (CGI)
To describe the clinical response (as measured by Clinical Global Impression \[CGI\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Clinical Global Impression (CGI) is a 3-item clinician-rated scale that measures the severity of psychopathology (CGI-S), the global improvement of the patient (CGI-I) and therapeutic response (CGI-E). CGI-S and CGI-I are rated on a 7-point scale. For CGI-S, a score of 1 indicates lack of illness and 7 indicates the greatest severity. For CGI-I, the score ranges from 1, referring to the biggest improvement, to 7, referring to the biggest worsening. CGI-E evaluates 2 dimensions of the therapeutic response, namely, the therapeutic effect and side effects, rated on 4 levels. The assessment is performed on a 4x4 scale, with scores ranging from 1 to 16. The CGI will be completed by the Investigator at V1 (only CGI-S) and V3 (or early termination visit) and the results will be entered into the eCRF
Time frame: At 24 weeks from treatment
Cognitive functioning (MoCA)
To describe the response in terms of cognitive functioning (as measured by Montreal Cognitive Assessment \[MoCA\] and Repeatable Battery for the Assessment of Neuropsychological Status \[RBANS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montreal Cognitive Assessment (MoCA) is a brief screening tool which includes 11 tasks assessing several cognitive domains, namely, memory, visuospatial abilities, executive functions, attention, concentration, language, and orientation to time and place. The total score ranges from 0 to 30. A score of 26 or above is considered normal, while scores below 26 indicate potential mild cognitive impairment or more serious. In addition, a correction for education is applied by adding 1 point for subjects with less than 12 years of education. The MoCA will be administered to the patient by the Investigator at V1 and V3 (or early termination visit) and the results will be entered into the eCRF.
Time frame: At 24 weeks from treatment
Sleep quality (SQS)
To describe the response in terms of sleep quality (as measured by the single-item Sleep Quality Scale \[SQS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Sleep Quality Scale (SQS) is a single-item validated questionnaire evaluating overall quality of sleep using a visual analogue scale (VAS), with values ranging from 0 (terrible) to 10 (excellent). The recall period for the scale is seven days. The SQS is completed by the patient at V1 and V3 (or early termination visit) and the results will be and entered into the eCRF by the Investigator.
Time frame: At 24 weeks from treatment
To describe the response in terms of quality of life (EQ-5D-5L)
To describe the response in terms of quality of life (as measured by the Euro-Quality of Life 5 dimensions - 5 level \[EQ-5D-5L\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L) is a brief and generic tool to measure patient-reported health status. It consists of two parts. EQ-5D-5L includes 5 questions covering 5 domains of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression). Each question is rated on 5 levels of response, ranging from no problems to extreme problems. The measure also includes a visual analogue scale (EQ-VAS) which requires patients to rate their own health from 0 to 100,representing, respectively, the worst and best imaginable health status. The EQ-5D-5L will be completed by the patient at V1 and V3 (or early termination visit) and the results will be entered into the eCRF by the Investigator.
Time frame: At 24 weeks from treatment
Absolute and relative frequency of patients
Analyze the response absolute and relative frequency of patients with moderate-severe MDD and with MCI discontinuing trazodone during the study period and reasons for discontinuation. Analyze the response absolute and relative frequency of patients with moderate-severe MDD and with MCI starting another anti-depressant during the study period and type of anti-depressant. Analyze the response absolute and relative frequency of concomitant medications.
Time frame: Over 24 weeks
Serious adverse events of prolonged release trazodone
Analyze the absolute and relative frequency of patients experiencing serious adverse events. Descriptive statistics will be provided for details of AEs, such as severity, outcome, seriousness, causality, and action taken. AEs will be coded using the MedDRA.
Time frame: Over 24 weeks
Drug related adverse events of prolonged release trazodone
Analyze absolute and relative frequency of patients experiencing drug related adverse events. Descriptive statistics will be provided for details of AEs, such as severity, outcome, seriousness, causality, and action taken. AEs will be coded using the MedDRA.
Time frame: Over 24 weeks
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 33 industry-sponsored observational studies under Depression, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.
Counting every sponsor, half of 495 studies reached it within 32 months; a quarter within 13 and three quarters within 62.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Dec 2026 and completion Jul 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aziende Chimiche Riunite Angelini Francesco S.p.A →